Two Sigma Investments LP Invests $1.50 Million in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Two Sigma Investments LP purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 112,458 shares of the company’s stock, valued at approximately $1,498,000. Two Sigma Investments LP owned approximately 0.43% of Eton Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Nantahala Capital Management LLC increased its stake in Eton Pharmaceuticals by 12.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock worth $14,898,000 after buying an additional 119,750 shares in the last quarter. Mink Brook Asset Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at $6,071,000. Cannell Capital LLC acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at $5,079,000. Parkman Healthcare Partners LLC raised its stake in shares of Eton Pharmaceuticals by 6.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock valued at $3,688,000 after acquiring an additional 16,664 shares in the last quarter. Finally, Aristides Capital LLC raised its stake in shares of Eton Pharmaceuticals by 20.8% in the fourth quarter. Aristides Capital LLC now owns 241,587 shares of the company’s stock valued at $3,218,000 after acquiring an additional 41,587 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $17.28 on Wednesday. Eton Pharmaceuticals, Inc. has a 1-year low of $3.18 and a 1-year high of $21.48. The stock has a market cap of $463.42 million, a PE ratio of -78.55 and a beta of 1.22. The stock’s fifty day moving average is $16.00 and its two-hundred day moving average is $14.78.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $14.33 million. On average, research analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ETON. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Craig Hallum increased their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Finally, B. Riley restated a “buy” rating and issued a $26.00 price target (up from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.